Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I : a clinical update
- Author
- DAVIS, Mark W1 ; FEIGE, Ulrich2 ; BENDELE, Alison M3 ; MARTIN, Steven W2 ; EDWARDS, Carl K4
[1] Clinical Development, Amgen Inc, Thousand Oaks, One Amgen Center Drive, Mail Stop 24-1-B, Thousand Oaks, California, 91320-1789, United States
[2] Department of Pharmacology, Amgen Inc, United States
[3] Bolder Path Inc, University of Colorado, United States
[4] Research and Development, Amgen Inc, United States - Source
Annals of the rheumatic diseases. 2000, Vol 59, pp i41-i43 ; SUP1 ; ref : 15 ref
- CODEN
- ARDIAO
- ISSN
- 0003-4967
- Scientific domain
- Rheumatology
- Publisher
- BMJ, London
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Keyword (fr)
- Agent biologique Antirhumatismal Chimiothérapie Chronique Efficacité traitement Essai clinique Facteur nécrose tumorale α Homme Mécanisme action Polyarthrite rhumatoïde Relation pharmacocinétique pharmacodynamie Récepteur biologique Traitement PEGsTNF-RI Cytokine Immunopathologie Maladie autoimmune Rhumatisme inflammatoire Système ostéoarticulaire pathologie
- Keyword (en)
- Biological agent Antirheumatic agent Chemotherapy Chronic Treatment efficiency Clinical trial Tumor necrosis factor α Human Mechanism of action Rheumatoid arthritis Pharmacokinetic pharmacodynamic relationship Biological receptor Treatment Cytokine Immunopathology Autoimmune disease Inflammatory joint disease Diseases of the osteoarticular system
- Keyword (es)
- Agente biológico Antireumático Quimioterapia Crónico Eficacia tratamiento Ensayo clínico Factor necrosis tumoral α Hombre Mecanismo acción Poliartritis reumatoidea Relación farmacocinética farmacodinamia Receptor biológico Tratamiento Citoquina Inmunopatología Enfermedad autoinmune Reumatismo inflamatorio Sistema osteoarticular patología
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02L Bones, joints and connective tissue. Antiinflammatory agents
- Discipline
- Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 793462
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Install on your browser
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:133:\"Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I : a clinical update\";s:9:\"\u0000*\u0000jtitle\";s:32:\"Annals of the rheumatic diseases\";s:9:\"\u0000*\u0000stitle\";s:15:\"Ann. rheum. dis\";s:7:\"\u0000*\u0000date\";s:4:\"2000\";s:9:\"\u0000*\u0000volume\";s:2:\"59\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:3:\"i41\";s:8:\"\u0000*\u0000epage\";s:3:\"i43\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0003-4967\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"DAVIS\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Mark W\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:4:{i:0;s:13:\"FEIGE, Ulrich\";i:1;s:17:\"BENDELE, Alison M\";i:2;s:16:\"MARTIN, Steven W\";i:3;s:15:\"EDWARDS, Carl K\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"ARDIAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:4:\"SUP1\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:133:\"Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I : a clinical update\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:3:\"BMJ\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:133:\"Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I : a clinical update\";s:9:\"\u0000*\u0000jtitle\";s:32:\"Annals of the rheumatic diseases\";s:9:\"\u0000*\u0000stitle\";s:15:\"Ann. rheum. dis\";s:7:\"\u0000*\u0000date\";s:4:\"2000\";s:9:\"\u0000*\u0000volume\";s:2:\"59\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:3:\"i41\";s:8:\"\u0000*\u0000epage\";s:3:\"i43\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0003-4967\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"DAVIS\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Mark W\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:4:{i:0;s:13:\"FEIGE, Ulrich\";i:1;s:17:\"BENDELE, Alison M\";i:2;s:16:\"MARTIN, Steven W\";i:3;s:15:\"EDWARDS, Carl K\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"ARDIAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:4:\"SUP1\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:133:\"Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I : a clinical update\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:3:\"BMJ\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:133:\"Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I : a clinical update\";s:9:\"\u0000*\u0000jtitle\";s:32:\"Annals of the rheumatic diseases\";s:9:\"\u0000*\u0000stitle\";s:15:\"Ann. rheum. dis\";s:7:\"\u0000*\u0000date\";s:4:\"2000\";s:9:\"\u0000*\u0000volume\";s:2:\"59\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:3:\"i41\";s:8:\"\u0000*\u0000epage\";s:3:\"i43\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0003-4967\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"DAVIS\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Mark W\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:4:{i:0;s:13:\"FEIGE, Ulrich\";i:1;s:17:\"BENDELE, Alison M\";i:2;s:16:\"MARTIN, Steven W\";i:3;s:15:\"EDWARDS, Carl K\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"ARDIAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:4:\"SUP1\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:133:\"Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I : a clinical update\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:3:\"BMJ\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:133:\"Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I : a clinical update\";s:9:\"\u0000*\u0000jtitle\";s:32:\"Annals of the rheumatic diseases\";s:9:\"\u0000*\u0000stitle\";s:15:\"Ann. rheum. dis\";s:7:\"\u0000*\u0000date\";s:4:\"2000\";s:9:\"\u0000*\u0000volume\";s:2:\"59\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:3:\"i41\";s:8:\"\u0000*\u0000epage\";s:3:\"i43\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0003-4967\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"DAVIS\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Mark W\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:4:{i:0;s:13:\"FEIGE, Ulrich\";i:1;s:17:\"BENDELE, Alison M\";i:2;s:16:\"MARTIN, Steven W\";i:3;s:15:\"EDWARDS, Carl K\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"ARDIAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:4:\"SUP1\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:133:\"Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I : a clinical update\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:3:\"BMJ\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:133:\"Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I : a clinical update\";s:9:\"\u0000*\u0000jtitle\";s:32:\"Annals of the rheumatic diseases\";s:9:\"\u0000*\u0000stitle\";s:15:\"Ann. rheum. dis\";s:7:\"\u0000*\u0000date\";s:4:\"2000\";s:9:\"\u0000*\u0000volume\";s:2:\"59\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:3:\"i41\";s:8:\"\u0000*\u0000epage\";s:3:\"i43\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0003-4967\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"DAVIS\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Mark W\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:4:{i:0;s:13:\"FEIGE, Ulrich\";i:1;s:17:\"BENDELE, Alison M\";i:2;s:16:\"MARTIN, Steven W\";i:3;s:15:\"EDWARDS, Carl K\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"ARDIAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:4:\"SUP1\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:133:\"Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I : a clinical update\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:3:\"BMJ\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
